Please enable Javascript
Kerri Fitzgerald
Articles by Kerri Fitzgerald
New PET Imaging Agent Can Predict Response to CAR T-Cell Therapy
Kerri Fitzgerald
SNMMI
|
June 15, 2022
The approach may help inform clinical decision-making early in treatment.
Read More
Phase 2 Study Supports Radionuclide Alpha Therapy in Patients With Advanced Neuroendocrine Tumors
Kerri Fitzgerald
SNMMI
|
June 14, 2022
The authors of the study won the 2022 SNMMI Abstract of the Year Award.
Read More
Study: New AI Scan Strategy Can Cut Radiation Exposure in Half
Kerri Fitzgerald
SNMMI
|
June 14, 2022
The novel artificial intelligence can produce high-quality PET/CT images while decreasing radiation exposure to ...
Read More
Myelofibrosis Associated With Subsequent Development of Multiple Myeloma
Kerri Fitzgerald
Oncology
|
February 16, 2021
A study published in the European Journal of Haematology found that a diagnosis of primary myelofibrosis (MF) or ...
Read More
Radiographic Osteoarthritis Predicts Patient Satisfaction with Contralateral Knee Replacement
Kerri Fitzgerald
Osteoarthritis
|
February 11, 2021
In patients with an unsatisfactory response to first knee replacement, the best predictor of achieving a satisfactory ...
Read More
Systematic Review Compares Allogeneic Hematopoietic Cell Transplant Versus Gene Therapy in Sickle Cell Disease
Kerri Fitzgerald
ASH Annual Meeting 2020
|
December 17, 2020
Sickle cell disease (SCD) shortens life expectancy and leads to morbidity. Recent advancements in allogeneic ...
Read More
Zeta Globin Gene Expression May Lead to Therapy for Alpha Thalassemia Major
Kerri Fitzgerald
ASH Annual Meeting 2020
|
December 17, 2020
Alpha-globin mutations are common, and the number and type of mutated alleles will determine the severity of subsequent ...
Read More
Long-Term Data Support AMT-060 Gene Therapy in Hemophilia B
Kerri Fitzgerald
ASH Annual Meeting 2020
|
December 17, 2020
At the all-virtual 62nd ASH Annual Meeting & Exposition, researchers presented data from an ongoing phase I/II trial ...
Read More
Denosumab Versus Alendronate for Osteoporosis in Patients Receiving Long-Term Glucocorticoids
Kerri Fitzgerald
Osteoporosis
|
December 14, 2020
A study published as part of the American College of Rheumatology Annual Meeting compared denosumab versus alendronate ...
Read More
Hematologist Discusses the Impact a Myeloma CAR T-Cell Approval Would Have on the Treatment Landscape
Kerri Fitzgerald
Oncology
|
December 1, 2020
Ankit Kansagra, MD, an assistant professor in the Department of Internal Medicine at UT Southwestern Medical Center ...
View More
Study Identifies Four Features That Impact Survival in Patients with Multiple Myeloma and COVID-19
Kerri Fitzgerald
COVID-19
|
November 20, 2020
A study published in Blood identified the following factors as predictive of worse outcomes for patients with multiple ...
Read More
Romosozumab Improves Hip, Lumbar Spine BMD, But Treatment Sequencing Impacts Outcomes
Kerri Fitzgerald
Osteoporosis
|
November 17, 2020
Romosozumab produces “substantial” bone mineral density (BMD) gains at the total hip and lumbar spine within one ...
Read More
Does the Addition of Ixazomib to Lenalidomide and Dexamethasone Improve Survival in MM?
Kerri Fitzgerald
Oncology
|
September 16, 2020
A study presented at the 2020 Society of Hematologic Oncology Annual Meeting found that the addition of ixazomib to ...
Read More
Carfilzomib or Bortezomib for Triplet Combination Therapy for Multiple Myeloma?
Kerri Fitzgerald
Oncology
|
September 9, 2020
Researchers compared the efficacy of lenalidomide and dexamethasone paired with carfilzomib or bortezomib for the ...
Read More
Survival Outcomes with Maintenance Therapy Versus Observation for Multiple Myeloma
Kerri Fitzgerald
Oncology
|
August 26, 2020
Maintenance therapy increases survival in patients with multiple myeloma (MM) compared with observation, according to a ...
Read More
FDA Approves Retevmo® for RET-Mutated Lung, Thyroid Cancers
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
May 14, 2020
The U.S. Food and Drug Administration approved Retevmo® (selpercatinib) for three types of RET-mutated cancer: adults ...
Read More
FDA Approves Lynparza® Plus Avastin® Combo for Gynecologic Cancers
Kerri Fitzgerald
Oncology
|
May 13, 2020
The U.S. Food and Drug Administration (FDA) approved Lynparza® (olaparib) in combination with Avastin® (bevacizumab) ...
Read More
FDA Approves Targeted Treatment for Lung Cancer Along With Companion Diagnostic
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
May 11, 2020
The U.S. Food and Drug Administration (FDA) approved Tabrecta™ (capmatinib) for adults with metastatic non-small cell ...
Read More
Addition of Tislelizumab to Chemotherapy in Frontline Setting Improves Survival for Lung Cancer
Kerri Fitzgerald
Non-Small Cell Lung Cancer
|
April 15, 2020
Frontline tislelizumab plus chemotherapy significantly improved progression-free survival (primary endpoint) compared ...
Read More
FDA Approves New Combination for BRAF V600E-Mutated Colorectal Cancer
Kerri Fitzgerald
Colorectal Cancer
|
April 14, 2020
The U.S. Food and Drug Administration (FDA) approved Braftovi® (encorafenib) in combination with cetuximab for ...
Read More
Load More